Lung-Resident Memory Th2 Cells in Asthma
NCT03455959 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37
Last updated 2026-04-17
Summary
Determining how memory T helper type 2 (Th2) initiate recall responses to aeroallergens has the potential to change the therapeutic approach to allergic asthma, the most common asthma subtype. \~5-10% of effector Th2 cells recruited into the lung give rise to long-lived tissue resident memory cells that are poised to respond upon allergen re-exposure.Consequently, targeting memory Th2 cell activation is an attractive therapeutic strategy. However, it is not well understood how allergen inhalation initiates a memory Th2 cell response in the lung. The focus of this new study on the role of lung-resident memory Th2 cells in orchestrating the recall response to allergen in the lung, including the recruitment and activation of circulating Th2 cells, is a natural, timely and exciting extension of the investigators' ongoing Allergen Challenge Protocol.
Conditions
- Asthma, Allergic
Interventions
- PROCEDURE
-
Bronchoscopy/BAL
Participants may receive 3 inhalations (90 ug ea) of albuterol to minimize bronchoconstriction. Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary. 2% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia. 1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia. The bronchoscope is then passed through the vocal cords into the trachea. Throughout the procedure, all participants will have continuous blood pressure, heart rate, and oxygen saturation monitoring. Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals. Once in the lung, aliquots of sterile saline are instilled into two subsegments of the right middle lobe (preferred and if not possible then the right upper lobe) and withdrawn into a trap by gentle suction.
- PROCEDURE
-
Airway Brushing
After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. A second brush will then be introduced into an adjacent airway of the same lobe and gently glided back and forth on the airway epithelium 10 times in 2 different locations as was done with the first brush. The second brush will also be placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Andrew D. Luster, M.D.,Ph.D.
lead OTHER
Principal Investigators
-
Andrew D Luster · MGH
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-05-23
- Primary Completion
- 2024-11-15
- Completion
- 2027-12-15
Countries
- United States
Study Locations
More Related Trials
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
NCT00595491 ·Status: RECRUITING ·Phase: PHASE1
-
Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity
NCT00217854 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma
NCT00394654 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
NCT02135692 ·Status: COMPLETED ·Phase: PHASE3
-
Role of microRNAs in T Cell-Driven Inflammation in Asthma
NCT01484691 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma
NCT00659659 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
NCT01842607 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults
NCT00968669 ·Status: COMPLETED ·Phase: PHASE2
-
Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma
NCT03784781 ·Status: WITHDRAWN
-
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
NCT01691521 ·Status: COMPLETED ·Phase: PHASE3
-
Innate Immunity in Allergic Asthma
NCT06068335 ·Status: RECRUITING
-
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
NCT00576069 ·Status: RECRUITING
-
Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma
NCT00001909 ·Status: COMPLETED ·Phase: PHASE2
-
How Airway Remodeling and Hyperresponsiveness Contribute to Airflow Obstruction in Asthma
NCT00186693 ·Status: WITHDRAWN
-
Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
NCT02230189 ·Status: COMPLETED ·Phase: PHASE2
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
NCT01225913 ·Status: RECRUITING ·Phase: PHASE4
-
Role of T-Cells in Asthma
NCT00001408 ·Status: COMPLETED
-
AIM2ACT: A Mobile Health Tool to Help Adolescents Self-Manage Asthma
NCT04448002 ·Status: COMPLETED ·Phase: NA
-
Imaging Study of the Lungs During an Allergic Asthma Attack
NCT01547286 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
NCT01238861 ·Status: COMPLETED ·Phase: PHASE2
-
iTRACC (Improving Technology-Assisted Recording of Asthma Control in Children)
NCT02994238 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
NCT00725582 ·Status: COMPLETED ·Phase: PHASE1
-
Allergy Immunotherapy for the Reduction of Asthma
NCT01028560 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)
NCT01056159 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study in Patients With Symptomatic Steroid-Naive Asthma
NCT00024544 ·Status: COMPLETED ·Phase: PHASE2